(Albany, US) DelveInsight has launched a new report on Migraine Market
Delve Insight’s Migraine Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Migraine market report provides current treatment practices, emerging drugs, Migraine market share of the individual therapies, current and forecasted Migraine market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Migraine treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Migraine is a neurological disorder, which involves nerve pathways and brain chemicals. It is an uncertainty in the way the brain deals with incoming sensory information, and that uncertainty can be influenced by physiological changes like sleep, exercise and hunger and is one of the most common and most prevalent neurological diseases with extremely incapacitating neurological symptoms. It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, in one-third of migraine attacks, both sides are found to be affected.
Request for free sample page: – https://www.delveinsight.com/sample-request/migraine-market
Migraine Treatment
The DelveInsight Migraine market report gives a thorough understanding of the Migraine by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. This segment of the report covers the detailed diagnostic methods or tests for Migraine. It covers the details of conventional and current medical therapies available in the Migraine market for the treatment of the condition. It also provides Migraine treatment algorithms and guidelines in the United States, Europe, and Japan
Migraine Market
There has been a significant advancement in the understanding of the migraine pathophysiology, which has led to the improved characterization and diagnosis of the clinical features. For treatment to be effective, the correct diagnosis must be made followed by choice of treatment, taking into account the severity and frequency of attacks, other symptoms, patient preference, history of treatment, and comorbid conditions. Treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation. Preventive treatment is maintained for months or even years to reduce the frequency, severity, and duration of attacks. Patients taking preventive medications may also use acute and preventive medications.
Many medications are available to treat migraine, and the choice depends on the severity and frequency of headaches. These categories of drugs include specific and non-specific treatments. Non-specific treatments are effective for any pain disorder and include non-steroidal anti-inflammatory drugs (NSAIDs), combined with analgesics, opioids, neuroleptics/antiemetics, and corticosteroids. Furthermore, specific therapies, such as compounds containing ergotamine, DHE, and triptans, are also effective for the treatment of migraine and related disorders. Despite various improvements in the research, migraine remains underdiagnosed and undertreated, leading to a higher unmet medical need with severe patients. In May 2018, the US FDA approved a new drug, Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is the first FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. As per expert opinions, this drug is anticipated to change the current treatment landscape and impact the migraine drug market significantly.
Migraine Report Scope
- The report covers the descriptive overview of Migraine, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Migraine epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Migraine are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Migraine market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Migraine market
Request for free sample page: – https://www.delveinsight.com/sample-request/migraine-market
Table of content
1. Key Insights
2. Executive Summary of Migraine
3. Competitive Intelligence Analysis for Migraine
4. Migraine: Market Overview at a Glance
5. Migraine: Disease Background and Overview
6. Patient Journey
7. Migraine Epidemiology and Patient Population
8. Migraine Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Migraine Treatment
11. Marketed Products
12. Migraine Emerging Therapies
13. Migraine: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Migraine
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Migraine market
- To understand the future market competition in the Migraine market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Migraine in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Migraine market
- To understand the future market competition in the Migraine market
Related Reports
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/